CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on September 20, 2006
Clinical Journal of the American Society of Nephrology
© 2006 American Society of Nephrology
doi: 10.2215/CJN.02211205
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.02211205v1
1/6/1241    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tourret, J.
Right arrow Articles by Bagnis, C. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tourret, J.
Right arrow Articles by Bagnis, C. I.

Received December 21, 2005
Accepted on August 8, 2006

ORIGINAL ARTICLES

Outcome and Prognosis Factors in HIV-Infected Hemodialysis Patients

Jérôme Tourret *1, Isabelle Tostivint *, Sophie Tézenas du Montcel {dagger}, Jennifer Bragg-Gresham {ddagger}, Svétlana Karie *, Cécile Vigneau {sect}, Jean-Baptiste Guiard-Schmid ||, Gilbert Deray *, and Corinne Isnard Bagnis *

Departments of *Nephrology and {dagger}Biostatistics and Medical Information, Hôpital Pitié-Salpêtrière, and Departments of {sect}Nephrology and ||Infectious Diseases, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France; and {ddagger}Arbor Research Collaborative for Health (formerly University Renal Research and Education Association), Ann Arbor, Michigan


1 To whom correspondence should be addressed. E-mail: jtourret{at}yahoo.com.


   Abstract

HIV-infected patients who are on hemodialysis have a worse prognosis than noninfected patients who are on hemodialysis. Their outcome in the highly active antiretroviral therapy (HAART) era remains unclear. Outcomes in patients who were enrolled in the French Dialysis in HIV/AIDS (DIVA) cohort were determined in a 2-yr prospective follow-up. All HIV-infected patients who were on hemodialysis in France on January 1, 2002, were included and followed prospectively until January 1, 2004. Patients’ survival was examined by Kaplan-Meier method, and mortality risk factors were examined using uni- and multicovariate analyses. Survival was compared with that of 584 hemodialysis patients who did not have HIV or diabetes and were enrolled in the French Dialysis Outcomes and Practice Patterns Study II (DOPPS II) in the same period (after standardization for the average age, gender, and ethnicity of the DIVA cohort). A total of 27,577 patients were receiving hemodialysis in France at the beginning of the study; 164 (0.59%) were infected with HIV, 72% were male, mean age was 44.8 ± 10.9 yr, and 65% were black. The 2-yr survival rate was 89 ± 2% and statistically indistinguishable from the survival of the French cohort extracted from the DOPPS II study. Significant mortality risk factors were low CD4 cell count (hazard ratio [HR] 1.4/100 CD4 cells per mm3 lower), high viral load (HR 2.5/1 Log per ml), absence of HAART (HR 2.7), and a history of opportunistic infection (HR 3.7), the last two being independent (HR 2.6 and 3.6, respectively). Survival of HIV-infected patients who are hemodialysis has greatly improved. A prospective cohort of paired hemodialysis patients with and without HIV is required to compare better their mortality in the HAART era.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Society of Nephrology.